Paper41764403
Ultrasound-Responsive Engineered Bacteria for Targeted Cancer Therapy: Strategies, Mechanisms, and Applications.
Wang X and 5 others. Adv Sci (Weinh), 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Ultrasound-Responsive Engineered Bacteria for Targeted Cancer Therapy: Strategies, Mechanisms, and Applications. Papers, record 41764403. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41764403
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Ultrasound-Responsive Engineered Bacteria for Targeted Cancer Therapy: Strategies, Mechanisms, and Applications.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Bacteria | Major topic |
| Drug Delivery Systems | Major topic |
| Humans | |
| Animals |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CUGD0200400424 | Harbin Institute of Technology Zhengzhou Research Institute Research Launch Fund | PubMed | ||
| CUGD0200600223 | Harbin Institute of Technology Zhengzhou Research Institute Research Launch Fund | PubMed | ||
| CUGD0200800125 | Young Scientists Studio | PubMed | ||
| 242102311235 | Henan Provincial Science and Technology Research Project | PubMed | ||
| 254200510053 | Henan Province Science and Technology Innovation Talent Program | PubMed | ||
| 2024M754162 | Postdoctoral Research Foundation of China | PubMed | ||
| 52522215 | National Natural Science Foundation of China | PubMed | ||
| 82171963 | National Natural Science Foundation of China | PubMed |
Source PubMed
References101
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40104641 | Ultrasound-responsive engineered bacteria mediated specific controlled expression of catalase and efficient radiotherapy. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/40104641 | PubMed |
| 2 | 35708251 | Tunable Temperature-Sensitive Transcriptional Activation Based on Lambda Repressor. | ACS Synth Biol | 2022 | https://conductscience.org/library/papers/35708251 | PubMed |
| 3 | 38487163 | Ultrasound combined with microbubble mediated immunotherapy for tumor microenvironment. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38487163 | PubMed |
| 4 | 38975322 | Ultrasound -Induced Thermal Effect Enhances the Efficacy of Chemotherapy and Immunotherapy in Tumor Treatment. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/38975322 | PubMed |
| 5 | 39208935 | The advance of ultrasound-enabled diagnostics and therapeutics. | J Control Release | 2024 | https://conductscience.org/library/papers/39208935 | PubMed |
| 6 | 39834364 | A comprehensive review of probiotics and human health-current prospective and applications. | Front Microbiol | 2024 | https://conductscience.org/library/papers/39834364 | PubMed |
| 7 | 37875910 | Engineered live bacteria as disease detection and diagnosis tools. | J Biol Eng | 2023 | https://conductscience.org/library/papers/37875910 | PubMed |
| 8 | 40680134 | Acoustic technologies for the orchestration of cellular functions for therapeutic applications. | Sci Adv | 2025 | https://conductscience.org/library/papers/40680134 | PubMed |
| 9 | 34374945 | High-Intensity Focused Ultrasound: A Review of Mechanisms and Clinical Applications. | Ann Biomed Eng | 2021 | https://conductscience.org/library/papers/34374945 | PubMed |
| 10 | 33114050 | Doxorubicin Improves Cancer Cell Targeting by Filamentous Phage Gene Delivery Vectors. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33114050 | PubMed |
| 11 | 35985374 | The promising interplay between sonodynamic therapy and nanomedicine. | Adv Drug Deliv Rev | 2022 | https://conductscience.org/library/papers/35985374 | PubMed |
| 12 | 32843638 | The updated landscape of tumor microenvironment and drug repurposing. | Signal Transduct Target Ther | 2020 | https://conductscience.org/library/papers/32843638 | PubMed |
| 13 | 31941712 | Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing. | Proc Natl Acad Sci U S A | 2020 | https://conductscience.org/library/papers/31941712 | PubMed |
| 14 | 38610042 | Bacteria-driven nanosonosensitizer delivery system for enhanced breast cancer treatment through sonodynamic therapy-induced immunogenic cell death. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/38610042 | PubMed |
| 15 | 30837696 | Engineering advanced cancer therapies with synthetic biology. | Nat Rev Cancer | 2019 | https://conductscience.org/library/papers/30837696 | PubMed |
| 16 | 39395706 | Multi-functional nanosonosensitizer-engineered bacteria to overcome tumor hypoxia for enhanced sonodynamic therapy. | Acta Biomater | 2024 | https://conductscience.org/library/papers/39395706 | PubMed |
| 17 | 34166726 | Targeting hypoxia for sensitization of tumors to apoptosis enhancement through supramolecular biohybrid bacteria. | Int J Pharm | 2021 | https://conductscience.org/library/papers/34166726 | PubMed |
| 18 | 38481806 | NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer. | Int J Biol Sci | 2024 | https://conductscience.org/library/papers/38481806 | PubMed |
| 19 | 36213533 | Macrophage-mediated tumor-targeted delivery of engineered Salmonella typhi murium VNP20009 in anti-PD1 therapy against melanoma. | Acta Pharm Sin B | 2022 | https://conductscience.org/library/papers/36213533 | PubMed |
| 20 | 38858780 | Bacterial outer membrane vesicle-cancer cell hybrid membrane-coated nanoparticles for sonodynamic therapy in the treatment of breast cancer bone metastasis. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/38858780 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42964597 | Engineered live biotherapeutic products: design decisions, failure modes, and clinical translation. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42964597 | PubMed |
| 42530837 | Bacterial-based cancer therapy: mechanisms and therapeutic advances. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42530837 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41764403
GET https://conductscience.org/api/papers/v1/41764403/references?page=2